StockNews.com Begins Coverage on IRIDEX (NASDAQ:IRIX)

Investment analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued on Thursday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 4.1 %

Shares of IRIDEX stock opened at $1.64 on Thursday. IRIDEX has a 1 year low of $1.27 and a 1 year high of $3.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. The company has a market capitalization of $27.28 million, a P/E ratio of -2.45 and a beta of 0.81. The business has a 50-day moving average of $1.66 and a two-hundred day moving average of $1.86.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The business had revenue of $11.58 million for the quarter. During the same period last year, the firm posted ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.